Metabolik Sendrom Obez Kadınlarda Cinsel İşlevi Nasıl Etkiler?

Year 2024, , 311 - 316, 29.10.2024

Büşra İplikçi , Bülent Can , Ayberk İplikçi , Mehmet Sargın

https://doi.org/10.18521/ktd.1524374

Abstract

Amaç: Metabolik sendrom (MetS), gitgide yaygınlaşan önemli bir halk sağlığı sorunudur. MetS; diabetes mellitus, arteriyel hipertansiyon ve aterosklerotik kalp hastalığı gibi hastalıklara ve kadın cinsel işlev bozukluğuna (FSD) yol açar. Ancak obez bireylerde MetS’un kadın cinsel işleviyle ilişkisi belirsizdir. Çalışmamızda obez kadınlar ve MetS'li obez kadınlar karşılaştırıldı. Her iki grup arasında cinsel işlev bozukluğu açısından fark olup olmadığını saptamayı amaçladık.
Yöntem: Çalışmaya Ocak-Nisan 2022 tarihleri arasında merkezimizin obezite polikliniğine başvuran 21-51 yaş aralığındaki 114 hasta dahil edildi. Çalışma kriterlerini karşılayan hastalar sosyodemografik veri anketi, Kadın Cinsel İşlev İndeksi (FSFI) ve Beck Depresyon Envanteri'ni (BDI) yanıtladılar. Ziyaret sırasında antropometrik ölçümler ile kan basıncı ölçümleri yapıldı ve laboratuvar sonuçları kaydedildi.
Bulgular: Hastaların 73’ü (%64) sadece obez iken 41’i (%36) obezite ile birlikte MetS tanısı almıştı. İki grup arasında demografik veriler, klinik özellikler, BDI puanları ve FSFI toplam puanı açısından anlamlı fark saptanmadı. FSFI alt parametrelerinden biri olan lubrikasyon MetS'li grupta düşük bulunurken (p=0,028), diğer alt parametrelerde fark görülmedi.
Sonuç: Bu çalışmada, uyarılma sorununun bir işareti olan lubrikasyonun MetS'dan etkilendiğini gösterdik. MetS, obezite, arteriyel hipertansiyon, diabetes mellitus gibi FSD için risk faktörleri olan hastalar göz ardı edilmemelidir. Böylece FSD'nin genel sağlık üzerine olası etkilerinin önüne geçmek mümkün olacaktır.

Keywords

Biyoelektrik empedans, Kadın cinsel işlev bozukluğu, Metabolik sendrom, Obezite

How Does Metabolic Syndrome Affect Sexual Function in Obese Women?

Abstract

Objective:Metabolic syndrome (MetS) is significant public health concern with a rising prevalence. MetS leads to diseases such as diabetes mellitus, arterial hypertension (HTN) and atherosclerotic heart disease, as well as female sexual dysfunction (FSD). However, the relationship of MetS to female sexual function in obese woman is unclear. In our study, obese women and obese women with MetS were compared. We aimed to determine whether there was a difference between the two groups in terms of FSD.
Method:The study included 114 patients, aged 21-51, who visited the obesity outpatient clinic of our center from January to April 2022. Patients who met the study criteria answered the sociodemographic data questionnaire, Female Sexual Function Index (FSFI), and the Beck Depression Inventory (BDI). Anthropometric measurements and blood pressure assessments were conducted during the visit, and blood tests were recorded.
Results:Seventy-three (64%) patients were only obese, and 41 (36%) had a diagnosis of MetS with obesity. There was no significant difference between the two groups in terms of demographic data, clinical features, BDI scores, and FSFI total score. Lubrication, one of the FSFI subparameters, was found to be low in the group with MetS (p=0.028), while there was no difference in other subparameters.
Conclusions:In this study, we showed that lubrication as a sign of arousal problem is affected by MetS. Patients with risk factors for FSD such as MetS, obesity, HTN, diabetes mellitus should not be ignored. Thus, it will be possible to prevent the effects of FSD on general health.

Keywords

Bioelectrical impedance, Female sexual dysfunction, Metabolic syndrome, Obesity

Ethical Statement

The Ethics Committee of Istanbul Medeniyet University reviewed and approved the study (Approval No. 2021/0622).

Supporting Institution

None.

Thanks

None.

References

• 1. Berman JR, Goldstein I. Female sexual dysfunction. Urol Clin North Am. 2001;28(2):405-16.
• 2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.
• 3. Türkiye Endokrinoloji ve Metabolizma Derneği. Obezite tanı ve tedavi kılavuzu 2019 (8. Baskı). Bayt Grafik Tasarım ve Yayın Hizmetleri.
• 4. World health organization. Overweight and obesity report fact sheet. Available: https://www.who.int/news-room/fact-sheets/detail/ obesity-and-overweight [Accessed 1 Mar 2022].
• 5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28.
• 6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
• 7. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629–36.
• 8. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The Metabolic Syndrome: A Global Public Health Problem and A New Definition. J Atheroscler Thromb. 2005;12(6):295–300.
• 9. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
• 10. Oksuz E, Malhan S. Reliability and validity of the Female Sexual Function Index in Turkish population. Sendrom. 2005;17:54–60.
• 11. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1-20.
• 12. Hisli, N. Beck Depresyon Envanterinin üniversite öğrencileri için geçerliği, güvenirliği. Psikoloji dergisi 1989; 7(23), 3-13.
• 13. Oksuz E, Malhan S. Prevalence and risk factors for female sexual dysfunction in Turkish women. J Urol. 2006;175(2):654-8; discussion 658.
• 14. Graziottin A. Prevalence and evaluation of sexual health problems--HSDD in Europe. J Sex Med. 2007;4 Suppl 3:211-9.
• 15. Garcia S, Moreno S, Aponte H. Prevalence of Sexual Dysfunction in Female Outpatients and Personnel at a Colombian Hospital: Correlation with Hormonal Profile. J Sex Med. 2008;5(5):1208–13.
• 16. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine Aspects of Female Sexual Dysfunction. J Sex Med. 2004;1(1):82–6. 17. Althof SE, Leiblum SR, Chevret-Measson M, Hartmann U, Levine SB, McCabe M, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med. 2005;2(6):793-800.
• 18. Kirchengast S, Hartmann B, Gruber D, Huber J. Decreased sexual interest and its relationship to body build in postmenopausal women. Maturitas. 1996;23(1):63–71.
• 19. Adolfsson B, Elofsson S, Rössner S, Undén A-L. Are Sexual Dissatisfaction and Sexual Abuse Associated with Obesity? A Population-Based Study. Obes Res. 2004;12(10):1702–9.
• 20. Bajos N, Wellings K, Laborde C, Moreau C; CSF Group. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ. 2010;340:c2573.
• 21. Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res. 2005;17(3):224-6.
• 22. Kadioglu P, Yetkin DO, Sanli O, Yalin AS, Onem K, Kadioglu A. Obesity might not be a risk factor for female sexual dysfunction. BJU Int. 2010;106(9):1357–61.
• 23. Traish AM, Botchevar E, Kim NN. Biochemical Factors Modulating Female Genital Sexual Arousal Physiology. J Sex Med. 2010;7(9):2925–46.
• 24. De Franciscis P, Mainini G, Messalli EM, Trotta C, Luisi A, Laudando E, et al. Arterial hypertension and female sexual dysfunction in postmenopausal women. Clin Exp Obstet Gynecol. 2013;40(1):58–60.
• 25. Giuliano F, Droupy S. Dysfonction érectile [Erectile dysfunction]. Prog Urol. 2013 Jul;23(9):629-37. French.
• 26. Doumas M, Anyfanti P, Lazaridis N. Effects of antihypertensive therapy on female sexual dysfunction. J Hypertens. 2012;30(6):1263–4.